In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research 1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including eleven sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.

Bristol Institute of Transfusion Sciences NHS Blood and Transplant Filton United Kingdom

Department Immunology Leiden University Medical Center The Netherlands

Department LEMP University of Antwerp Belgium

Department of Haematology Erasmus Medical center Rotterdam The Netherlands

Department of Haematology John Radcliffe Hospital Oxford University Hospitals NHS Foundation Trust United Kingdom

Department of Hematology and Blood transfusion Military University Hospital Prague Czech Republic

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital University of Bern Switzerland

Department of Hematology University Hospital Basel Switzerland

Department of Laboratory Medicine Lund University Sweden

Department of Transfusion Medicine Sanquin Blood Bank Amsterdam The Netherlands

Etablissement Français du Sang Université Paris Est Créteil Créteil France

European Centre for Disease Prevention and Control Solna Sweden

Faculty of Biology and Medicine University of Lausanne Switzerland

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

Indian Institute of Technology Palakkad Kerala India

Institut für Immunologie und Transfusionsmedizin Universitätsmedizin Greifswald Germany

Institut National de la Santé et de la Recherche Médicale Centre de Recherche des Cordeliers Sorbonne Université Université de Paris France

Laboratoire d'Excellence GR Ex Paris France

National Health Service Blood and Transplant London United Kingdom

NHS Blood and Transplant London United Kingdom

Radcliffe Department of Medicine University of Oxford and Oxford BRC Haematology Theme United Kingdom

Regional Blood Transfusion Service Swiss Red Cross Basel Switzerland

Sanquin Blood Supply Amsterdam The Netherlands

Sanquin Research and Landsteiner Laboratory Amsterdam UMC Department of Hematopoiesis University of Amsterdam The Netherlands

Sanquin Research and Landsteiner Laboratory Amsterdam UMC UvA The Netherlands

School of Biochemistry Biomedical Sciences Building University Walk Bristol United Kingdom

Transfusion Medicine Leiden University Medical Center Leiden University The Netherlands

Transfusion Medicine NHS Blood and Transplant Oxford United Kingdom

University Clinic Hospital University of Barcelona Spain

Uppsala University IGP Sweden

See more in PubMed

Engert A, Balduini C, Brand A, et al. . The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101:115–208. PubMed PMC

Mueller MM, Van Remoortel H, Meybohm P, et al. ; ICC PBM Frankfurt 2018 Group. Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA. 2019;321:983–997. PubMed

Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. . Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA. 2021;325:552–560. PubMed PMC

Tay J, Allan DS, Chatelain E, et al. . Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial. J Clin Oncol. 2020;38:1463–1473. PubMed

Libster R, Pérez Marc G, Wappner D, et al. . Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–618. PubMed PMC

Carson JL, Stanworth SJ, Alexander JH, et al. . Clinical trials evaluating red blood cell transfusion thresholds: an updated systematic review and with additional focus on patients with cardiovascular disease. Am Heart J. 2018;200:96–101. PubMed

Curley A, Stanworth SJ, Willoughby K, et al. . Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med. 2019;380:242–251. PubMed

Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. . Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387:2605–2613. PubMed

Bodilsen J, Mariager T, Vestergaard HH, et al. . Association of lumbar puncture with spinal hematoma in patients with and without coagulopathy. JAMA. 2020;324:1419–1428. PubMed PMC

Das M, Karnam A, Stephen-Victor E, et al. . Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy. Cell Death Dis. 2020;11:50. PubMed PMC

Galeotti C, Stephen-Victor E, Karnam A, et al. . Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. J Allergy Clin Immunol. 2019;144:524–535. e8. PubMed

Galeotti C, Kaveri SV, Bayry J. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunology. 2020;9:e1198. PubMed PMC

Al-Zuhairy A, Jakobsen J, Andersen H, et al. . Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy. Eur J Neurol. 2019;26:1289–1e82. PubMed

Sala TP, Crave JC, Duracinsky M, et al. . Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases. Autoimmun Rev. 2018;17:873–881. PubMed

Berger M, Harbo T, Cornblath DR, et al. . IgPro20, the polyneuropathy and treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. Immunotherapy. 2018;10:919–933. PubMed

Carlone G, Torelli L, Maestro A, et al. . Pentaglobin® efficacy in reducing the incidence of sepsis and transplant-related mortality in pediatric patients undergoing hematopoietic stem cell transplantation: a retrospective study. J Clin Med. 2020;9:E1592. PubMed PMC

Cui J, Wei X, Lv H, et al. . The clinical efficacy of intravenous IgM-enriched immunoglobulin (pentaglobin) in sepsis or septic shock: a meta-analysis with trial sequential analysis. Ann Intensive Care. 2019;9:27. PubMed PMC

Saha C, Das M, Patil V, et al. . Monomeric immunoglobulin A from plasma inhibits human Th17 responses in vitro independent of FcαRI and DC-SIGN. Front Immunol. 2017;8:275. PubMed PMC

Rossato E, Ben Mkaddem S, Kanamaru Y, et al. . Reversal of arthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway. Arthritis Rheumatol. 2015;67:1766–1777. PubMed

Kiessling P, Lledo-Garcia R, Watanabe S, et al. . The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9:eaan1208. PubMed

Ulrichts P, Guglietta A, Dreier T, et al. . Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128:4372–4386. PubMed PMC

Howard JF, Jr, Bril V, Burns TM, et al. . Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92:e2661–e2673. PubMed PMC

Newland AC, Sánchez-González B, Rejtő L, et al. . Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95:178–187. PubMed PMC

Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-an overview. Front Med (Lausanne). 2018;5:236. PubMed PMC

Quill E. Medicine. Blood-matching goes genetic. Science. 2008;319:1478–1479. PubMed

Gleadall NS, Veldhuisen B, Gollub J, et al. . Development and validation of a universal blood donor genotyping platform: a multinational prospective study. Blood Adv. 2020;4:3495–3506. PubMed PMC

Sanchez-Mazas A, Vidan-Jeras B, Nunes JM, et al. . Strategies to work with HLA data in human populations for histocompatibility, clinical transplantation, epidemiology and population genetics: HLA-NET methodological recommendations. Int J Immunogenet. 2012;39:459–72; quiz 473. PubMed PMC

Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? Am J Transplant. 2015;15:1148–1154. PubMed

Heidt S, Haasnoot GW, van de Linden-van Oevelen MJH, Claas FHJ. Highly sensitized patients are well-served by receiving a compatible organ offer based on acceptable mismatches. Front Immunol. 2021;12:687254. PubMed PMC

Wehmeier C, Karahan GE, Krop J, et al. . Donor-specific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method. Transplantation. 2020;104:1026–1032. PubMed

Hönger G, Niemann M, Schawalder L, et al. . Toward defining the immunogenicity of HLA epitopes: impact of HLA class I eplets on antibody formation during pregnancy. HLA. 2020;96:589–600. PubMed

Ainley LI, Hewitt PE. Haematology patients and the risk of transfusion transmitted infection. Br J Haematol. 2018;180:473–483. PubMed

de Niet A, Zaaijer HL, ten Berge I, et al. . Chronic hepatitis E after solid organ transplantation. Neth J Med. 2012;70:261–266. PubMed

Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol. 2012;159:135–142. PubMed PMC

Stanworth SJ, Killick S, McQuilten ZK, et al. . Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189:279–290. PubMed

Rebulla P. The long and winding road to pathogen reduction of platelets, red blood cells and whole blood. Br J Haematol. 2019;186:655–667. PubMed

McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion. 2019;59:1132–1146. PubMed

Giarratana MC, Rouard H, Dumont A, et al. . Proof of principle for transfusion of in vitro-generated red blood cells. Blood. 2011;118:5071–5079. PubMed PMC

Migliaccio AR, Whitsett C, Papayannopoulou T, et al. . The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell Stem Cell. 2012;10:115–119. PubMed PMC

Trakarnsanga K, Griffiths RE, Wilson MC, et al. . An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells. Nat Commun. 2017;8:14750. PubMed PMC

Do Sacramento V, Mallo L, Freund M, et al. . Functional properties of human platelets derived in vitro from CD34+ cells. Sci Rep. 2020;10:914. PubMed PMC

Mittra J, Tait J, Mastroeni M, et al. . Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells. N Biotechnol. 2015;32:180–190. PubMed

Heshusius S, Heideveld E, Burger P, et al. . Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells. Blood Adv. 2019;3:3337–3350. PubMed PMC

Moreau T, Evans AL, Vasquez L, et al. . Corrigendum: large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Commun. 2017;8:15076. PubMed PMC

Kupzig S, Parsons SF, Curnow E, et al. . Superior survival of ex vivo cultured human reticulocytes following transfusion into mice. Haematologica. 2017;102:476–483. PubMed PMC

Griffiths RE, Kupzig S, Cogan N, et al. . Maturing reticulocytes internalize plasma membrane in glycophorin A-containing vesicles that fuse with autophagosomes before exocytosis. Blood. 2012;119:6296–6306. PubMed PMC

Lopez-Yrigoyen M, Yang CT, Fidanza A, et al. . Genetic programming of macrophages generates an in vitro model for the human erythroid island niche. Nat Commun. 2019;10:881. PubMed PMC

Bernecker C, Ackermann M, Lachmann N, et al. . Enhanced ex vivo generation of erythroid cells from human induced pluripotent stem cells in a simplified cell culture system with low cytokine support. Stem Cells Dev. 2019;28:1540–1551. PubMed PMC

Hawksworth J, Satchwell TJ, Meinders M, et al. . Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing. EMBO Mol Med. 2018;10:e8454. PubMed PMC

Capellera-Garcia S, Pulecio J, Dhulipala K, et al. . Defining the minimal factors required for erythropoiesis through direct lineage conversion. Cell Rep. 2016;15:2550–2562. PubMed PMC

Blin A, Le Goff A, Magniez A, et al. . Microfluidic model of the platelet-generating organ: beyond bone marrow biomimetics. Sci Rep. 2016;6:21700. PubMed PMC

Prudent M, Stauber F, Rapin A, et al. . Small-scale perfusion bioreactor of red blood cells for dynamic studies of cellular pathways: proof-of-concept. Front Mol Biosci. 2016;3:11. PubMed PMC

Bayley R, Ahmed F, Glen K, et al. . The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors. J Tissue Eng Regen Med. 2018;12:e368–e378. PubMed PMC

Moura PL, Hawley BR, Mankelow TJ, et al. . Non-muscle myosin II drives vesicle loss during human reticulocyte maturation. Haematologica. 2018;103:1997–2007. PubMed PMC

Meinders M, Shoemark D, Dobbe JGG, et al. . Expression and retention of thymidine phosphorylase in cultured reticulocytes as a novel treatment for MNGIE. Mol Ther Methods Clin Dev. 2020;17:822–830. PubMed PMC